Since CD38 could consume NAD+, NAD+ would be elevated by CD38 knock-out and then might stimulate SIRT1 and PARP1 to induce T cell differentiation into Th1 subsets for enhancing the anti-tumor effects [41]. The gene discussed is PARP1; the disease is neoplasm.